SX-517

• Description :

  SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [ (35) S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model[1][2].

• UNSPSC :

  12352005

• Target :

  CXCR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/sx-517.html

• Concentration :

  10mM

• Purity :

  99.90

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OB(C1=CC=CC=C1CSC2=NC=C(C(NC3=CC=C(F)C=C3)=O)C=C2)O

• Molecular Formula :

  C19H16BFN2O3S

• Molecular Weight :

  382.22

• References & Citations :

  [1]2-[5- (4-Fluorophenylcarbamoyl) pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517) : Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57 (20) :8378-97. |[2]Ti H, et al. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs) . J Med Chem. 2019 Jul 11;62 (13) :5944-5978.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CXCR1; CXCR2

• CAS Number :

  [1240494-13-6]